Thus, enhanced sorafenib anti-tumor efficacy is achieved either by inhibiting the Wnt/β-catenin pathway activated by DDX5 loss (Fig. 7) or by overexpression of DDX5 (Fig. 8). Here, DDX5 is linked to neoplasm.